Assessment of the French colistin action plan
Abstract
The discovery of the plasmid resistance gene to colistin mcr-1 in 2015, profoundly changed the way this widely used molecule in veterinary medicine in France was considered. National management measures have been set up to reduce its use in animals, in line with European recom-mendations. Two objectives were defined: that of the AMEG in 2016, to reach a consumption of less than 5mg/kg in 3 to 4 years and that defined by the Ecoantibio2 national plan of a 50% reduction in the cattle, pig and poultry sectors in 5 years compared to the 2014-2015 use. In order to assess the effectiveness of these measures, French sales, usages and resistance surveillance data were analysed.